NCT00989352

Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma

Treatment of Patients Over 65 Years With Primary CNS Lymphoma: High-dose Methotrexate Combined With Chemo-immunotherapy Followed by Maintenance Therapy

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 56 (estimated)
• Sponsor: University Hospital Freiburg · Academic / Other
• Sex: All
• Age: 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether combined chemotherapy \[rituximab plus high dosage methotrexate, lomustine, and procarbazine\] followed by maintenance therapy with procarbazine is effective in the treatment of cerebral Non Hodgkin lymphoma \[PCNSL\] in patients \> 65 years.

Conditions

• Primary Non Hodgkin Lymphoma of the Central Nervous System

Interventions

Type	Name	Description
DRUG	Methotrexate	3g/m² i.v. max. 9 times
DRUG	Lomustine	110 mg/m² p.o., max. 3 times
DRUG	Procarbazine	60 mg/m² p.o. for 10 days, max. 3 times 100 mg p.o. for 5 days, max. 6 times
DRUG	Rituximab	375 mg/m² i.v., max. 10 times

Timeline

• Start date: 2009-09-01
• Primary completion: 2011-06-01
• Completion: 2011-09-01
• First posted: 2009-10-05
• Last updated: 2009-10-05

Locations

1 site across 1 country: Germany